See more : Wacom Co., Ltd. (WACMY) Income Statement Analysis – Financial Results
Complete financial analysis of Elevai Labs, Inc. Common Stock (ELAB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Elevai Labs, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Kuwer Industries Limited (KUWERIN.BO) Income Statement Analysis – Financial Results
- FDC Limited (FDC.NS) Income Statement Analysis – Financial Results
- Tonking New Energy Group Holdings Limited (8326.HK) Income Statement Analysis – Financial Results
- Kancera AB (publ) (KAN.ST) Income Statement Analysis – Financial Results
- Zoomd Technologies Ltd. (ZOMD.V) Income Statement Analysis – Financial Results
Elevai Labs, Inc. Common Stock (ELAB)
Industry: Biotechnology
Sector: Healthcare
About Elevai Labs, Inc. Common Stock
Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 1.71M | 766.28K | 827.00 | 0.00 |
| Cost of Revenue | 578.02K | 324.00K | 2.85K | 0.00 |
| Gross Profit | 1.13M | 442.28K | -2.02K | 0.00 |
| Gross Profit Ratio | 66.25% | 57.72% | -244.01% | 0.00% |
| Research & Development | 426.24K | 228.75K | 123.63K | 118.86K |
| General & Administrative | 3.37M | 1.54M | 602.73K | 95.94K |
| Selling & Marketing | 660.29K | 192.86K | 31.61K | 6.08K |
| SG&A | 4.03M | 1.80M | 633.96K | 102.99K |
| Other Expenses | -3.32M | -198.44K | -25.45K | 0.00 |
| Operating Expenses | 1.13M | 2.23M | 783.04K | 222.91K |
| Cost & Expenses | 5.47M | 2.55M | 785.89K | 222.91K |
| Interest Income | 5.56K | 7.70K | 0.00 | 0.00 |
| Interest Expense | 19.53K | 2.63K | 0.00 | 0.00 |
| Depreciation & Amortization | 11.65K | 6.51K | 2.76K | 221.84K |
| EBITDA | -4.27M | -1.78M | -782.30K | -1.07K |
| EBITDA Ratio | -249.35% | -232.52% | -94,594.92% | 0.00% |
| Operating Income | -3.67M | -1.79M | -785.06K | -221.84K |
| Operating Income Ratio | -214.24% | -233.37% | -94,928.66% | 0.00% |
| Total Other Income/Expenses | -632.45K | -11.98K | 321.00 | -1.07K |
| Income Before Tax | -4.30M | -1.80M | -784.74K | -222.91K |
| Income Before Tax Ratio | -251.17% | -234.94% | -94,889.84% | 0.00% |
| Income Tax Expense | 0.00 | -2.00 | 3.00 | -1.07K |
| Net Income | -4.30M | -1.80M | -784.74K | -222.91K |
| Net Income Ratio | -251.17% | -234.94% | -94,889.84% | 0.00% |
| EPS | -0.40 | -0.19 | -0.05 | -0.05 |
| EPS Diluted | -0.40 | -0.19 | -0.05 | -0.05 |
| Weighted Avg Shares Out | 10.75M | 9.53M | 17.33M | 4.41M |
| Weighted Avg Shares Out (Dil) | 10.75M | 9.53M | 17.33M | 4.41M |
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medic
Univest Securities, LLC Announces Closing of $8.0 Million Registered Follow-on Offering for its Client Elevai Labs Inc. (NASDAQ: ELAB)
New York, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered follow-on offering (the...
Dow Gains Over 50 Points; Elevai Labs Shares Plummet
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 50 points on Monday.
Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering
NEWPORT BEACH, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today announced that it has priced a public offering with gross proceeds to the Company expected to...
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications
Case Studies Highlight Potential of Elevai Exosome Technology in Melasma Care When Used with Laser Therapy. Early Results Show Synergistic Effects of Elevai Exosomes™ and Laser Treatments for Melasma Improvement, With No Recurrence After Six Months.
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc. Announces Encouraging Research Data Results Indicating Potential for Hair Restoration Using Proprietary
Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™
Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondria
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum
NEWPORT BEACH, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announces the completion of a clinical study examining the effectiveness of Elevai exosomes on facial appearance.
Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications
Preliminary data from the research study in partnership with Dalhousie University demonstrates that Elevai's hUMSC derived exosomes (“ELEVAI exosomes™”) contain over 800 proteins that are associated with wound healing, immunomodulation and remodeling of the skin's extracellular matrix (“ECM”). ELEVAI exosomes™ protein...
Source: https://incomestatements.info
Category: Stock Reports